How to improve adherence of guidelines for localized testicular cancer surveillance: A Delphi consensus study.

consensus de-escalation delphy method surveillance testicular germ cell cancer

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 04 09 2022
accepted: 29 09 2022
entrez: 3 11 2022
pubmed: 4 11 2022
medline: 4 11 2022
Statut: epublish

Résumé

Stage-I testicular germ-cell tumor (TGCT) has excellent cure rates. Surveillance is fully included in patient's management, particularly during the first years of follow-up. Surveillance guidelines differ between the academic societies, mainly concerning imaging frequency and long-term follow-up. We evaluated surveillance practice and schedules followed by French specialists and set up a DELPHI method to obtain a consensual surveillance program with an optimal schedule for patients with localized TGCT. First, an online survey on surveillance practice of stage-I TGCT based on clinical-cases was conducted among urologists, radiation-oncologists and medical-oncologists. These results were compared to ESMO/EAU and AFU guidelines. Then a panel of experts assessed surveillance proposals following a Delphi-CM. Statements were drafted after analysis of the previous survey and systematic literature review, with 2 successive rounds to reach a consensus. The study was conducted between July 2018 and May 2019. Concerning the first step: 61 participated to the survey (69% medical-oncologists, 15% urologists, 16% radiation-oncologists). About 65% of practitioners followed clinico-biological guidelines concerning 1 to 5 years of follow-up, but only 25% stopped surveillance after the 5th-year. No physician followed the EAU/ESMO guidelines of de-escalation chest imaging. Concerning the second step: 32 experts (78% medical-oncologists, 16% urologists, 6% radiation-oncologists) participated to the Delphi-CM. Thanks to Delphi-CM, a consensus was reached for 26 of the 38 statements. Experts agreed on clinico-biological surveillance modalities and end of surveillance after the 5th-year of follow-up. For seminoma, abdominal ultrasound was proposed as an option to the abdominopelvic (AP) scan for the 4th-year of follow-up. No consensus was reached regarding de-escalation of chest imaging. To conclude, the survey proved that French TGCT-specialists do not follow current guidelines. With Delphi-CM, a consensus was obtained for frequency of clinico-biological surveillance, discontinuation of surveillance after the 5th-year, stop of AP scan on the 4th-year of follow-up for seminoma. Questions remains concerning type and frequency of chest imaging.

Identifiants

pubmed: 36324582
doi: 10.3389/fonc.2022.1036190
pmc: PMC9619048
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1036190

Informations de copyright

Copyright © 2022 Da Silva, Fléchon, Coquan, Planchamp, Culine, Murez, Méjean, Pasquier, Chevreau, Fizazi, Thiery-Vuilemin and Joly.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Rev Mal Respir. 2010 Jun;27(6):644-50
pubmed: 20610079
N Engl J Med. 2007 Nov 29;357(22):2277-84
pubmed: 18046031
Eur J Cancer. 2017 Oct;84:354-359
pubmed: 28866371
Eur Urol Focus. 2021 Sep;7(5):1137-1142
pubmed: 33121935
Eur Urol. 2016 Aug;70(2):365-71
pubmed: 26996661
Am J Kidney Dis. 2002 May;39(5):930-6
pubmed: 11979336
Urol Oncol. 2021 Jul;39(7):400-408
pubmed: 33642227
Clin Colorectal Cancer. 2018 Mar;17(1):58-64
pubmed: 29157662
Eur Urol. 2015 Dec;68(6):1054-68
pubmed: 26297604
Can Urol Assoc J. 2022 Feb;16(2):26-33
pubmed: 34582333
Ann Oncol. 2018 Aug 1;29(8):1658-1686
pubmed: 30113631
Ann Oncol. 2002 Feb;13(2):237-42
pubmed: 11886000
Arch Intern Med. 2009 Dec 14;169(22):2071-7
pubmed: 20008689
Bull Cancer. 2016 Feb;103(2):190-8
pubmed: 26782078
Ann Oncol. 2014 Nov;25(11):2167-2172
pubmed: 25114021
World J Urol. 2022 Feb;40(2):327-334
pubmed: 34854948
JAMA. 1999 Oct 20;282(15):1458-65
pubmed: 10535437
Int J Urol. 2014 Aug;21(8):S1-6
pubmed: 24725194
J Urol. 2017 Mar;197(3 Pt 1):684-689
pubmed: 27663460
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Ann Oncol. 2010 May;21 Suppl 5:v140-6
pubmed: 20555065
J Med Internet Res. 2017 Mar 22;19(3):e83
pubmed: 28330830
Prog Urol. 2016 Nov;27 Suppl 1:S147-S165
pubmed: 27846929

Auteurs

Angélique Da Silva (A)

Centre François-Baclesse, Department of Medical Oncology, Caen, France.

Aude Fléchon (A)

Centre Léon Bérard, Department of Medical Oncology, Lyon, France.

Elodie Coquan (E)

Centre François-Baclesse, Department of Medical Oncology, Caen, France.
Centre François-Baclesse, Clinical Research Unit, Caen, France.

François Planchamp (F)

Institut Bergonié, Clinical Research Unit, Bordeaux, France.

Stéphane Culine (S)

Hôpital Saint-Louis, Department of Medical Oncology, Paris, France.

Thibaut Murez (T)

Hôpital Lapeyronie, Department of Urology, Montpellier, France.

Arnaud Méjean (A)

Georges Pompidou European Hospital, Assistance Publique Hôpitaux de Paris, Department of Urology, Paris, France.

David Pasquier (D)

Centre Oscar Lambret, Department of Radiation Oncology, Lille, France.

Christine Chevreau (C)

Oncopôle, Department of Medical Oncology, Toulouse, France.

Karim Fizazi (K)

Gustave Roussy, University of Paris Sud, Department of Medical Oncology, Villejuif, France.

Antoine Thiery-Vuilemin (A)

CHRU Besancon, Hôpital Jean Minjoz, Department of Medical Oncology, Besancon, France.

Florence Joly (F)

Centre François-Baclesse, Department of Medical Oncology, Caen, France.
Centre François-Baclesse, Clinical Research Unit, Caen, France.

Classifications MeSH